Syprine
NDC Package 25010-710-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Syprine is a medication used to treat a certain inherited disorder (Wilson's disease). Marketed by Aton Pharma, Inc., this product is identified by NDC 25010-710 and is authorized under FDA application NDA019194.

Identification & Billing

NDC Package Code
25010-710-15
Package Description
1 BOTTLE in 1 CARTON / 100 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
25010071015
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA

Clinical Specifications

Proprietary Name
Syprine
Dosage Form
-
Usage Information
This medication is used to treat a certain inherited disorder (Wilson's disease). This disorder causes too much copper to build up in the liver, brain, and other parts of the body. Trientine works by binding to copper, which helps your body get rid of extra copper. This can decrease symptoms such as problems with speech/swallowing/coordination, tiredness, lack of appetite, abdominal pain, yellowing eyes/skin, fluid buildup in the legs/abdomen, uncontrolled movements, or muscle stiffness.

Regulatory & Marketing

Labeler Name
Aton Pharma, Inc.
FDA Application #
NDA019194
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-08-1985
End Marketing Date
08-26-2016
Listing Expiration
08-26-2016
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 25010-710-15 identifies a specific commercial package of 1 bottle in 1 carton / 100 capsule in 1 bottle of Syprine, labeled by Aton Pharma, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aton Pharma, Inc. on November 08, 1985. The current certification is valid through August 26, 2016.

What are the primary indications for this medication?

This medication is used to treat a certain inherited disorder (Wilson's disease). This disorder causes too much copper to build up in the liver, brain, and other parts of the body. Trientine works by binding to copper, which helps your body get rid of extra copper. This can decrease symptoms such as problems with speech/swallowing/coordination, tiredness, lack of appetite, abdominal pain, yellowing eyes/skin, fluid buildup in the legs/abdomen, uncontrolled movements, or muscle stiffness.

How is this Aton Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 25010071015. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
25010-710-15
11-Digit CMS (5-4-2)
25010-0710-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.